Samsung BioLogics seeks to raise up to $2.5 billion from IPO
August 10, 2016 at 05:45 AM EDT
Samsung BioLogics Co., Samsung’s contract drug manufacturing unit, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion.